This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thaller, C. Articles by Kadmon, D. Search for Related Content PubMed PubMed Citation Articles by Thaller, C. Articles by Kadmon, D. Social Bookmarking                            What's this?

Fenretinide Therapy in Prostate Cancer: Effects on Tissue and Serum Retinoid Concentration

From the Department of Biochemistry, Matsunaga-Conte Prostate Cancer Research Center, and Scott Department of Urology, Baylor College of Medicine, Houston, TX.

Address reprint requests to Dov Kadmon, MD, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin St, Suite 2100, Houston, TX 77030.

PURPOSE: To examine the feasibility of using fenretinide (4-HPR) for the prevention and treatment of prostate cancer.

MATERIALS AND METHODS: We measured the impact of 4-HPR therapy on retinoid concentrations in vivo, in a mouse model of prostate cancer and clinically, in patients with prostate cancer who were given oral 4-HPR (200 mg/d) or placebo for 4 weeks before undergoing a radical prostatectomy.

RESULTS: Prostate tumors in mice treated with 4-HPR contained high levels of 4-HPR and of all-trans-retinoic acid (RA) and reduced levels of retinol (ROH). Patients given 4-HPR were found to have significantly higher concentrations of 4-HPR in the cancerous prostate as compared with the serum levels (463 nmol/L v 326 nmol/L; P = .049), but they were only 1/10 the levels found in mice and were far below the concentrations reported in human breast tissue. Serum and tissue ROH levels were reduced to less than half the concentrations found in untreated controls. RA concentrations in human serum and in cancerous prostates were not significantly affected by 4-HPR treatment, in contrast with the findings in mice.

CONCLUSION: The standard oral dose of 4-HPR proposed for breast cancer (200 mg/d) achieved only modest drug levels in the prostate and is unlikely to be effective for prostate cancer prevention or treatment. Higher doses need to be explored.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				O. W. Brawley, S. Lucia, and G. Andriole Chemoprevention of Prostate Cancer ASCO Educational Book, January 1, 2009; 2009(1): 62 - 64. [Abstract] [Full Text] [PDF]

				D. Serrano, L. Baglietto, H. Johansson, F. Mariette, R. Torrisi, M. Onetto, M. Paganuzzi, and A. Decensi Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer Clin. Cancer Res., March 1, 2005; 11(5): 2083 - 2088. [Abstract] [Full Text] [PDF]

				J. M. Alfaro, B. Fraile, M. V. T. Lobo, M. Royuela, R. Paniagua, and M. I. Arenas Immunohistochemical Detection of the Retinoid X Receptors {alpha}, {beta}, and {gamma} in Human Prostate J Androl, January 1, 2003; 24(1): 113 - 119. [Abstract] [Full Text] [PDF]

				F. Formelli Correspondence re: M. Follen et al., A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix. Clin. Cancer Res., 7: 3356-3365, 2001 Clin. Cancer Res., May 1, 2002; 8(5): 1310 - 1312. [Full Text] [PDF]